Biolegend, 311401, Purified anti-human HLA-A,B,C Antibody, 25μg

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8 + T cells. They play an important role in cell-mediated immune responses and tumor surveillance.
25μg
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: African Green, Baboon, Cat, Cow, Chimpanzee
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested Activ, Block, IHC-F, IP, WB - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per 106 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21. Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Darrow TL, et al. 1989. J. Immunol. 142:3329. Stern P, et al. 1987. J. Immunol. 138:1088. Tran TM, et al. 2001. Immunogenetics 53:440. Barbatis C, et al. 1981. Gut 22:985. Ayyoub M, et al. 2004. Cancer Immunity 4:7. DeFelice M, et al. 1990. Cell. Immunol. 126:420. Fayen J, et al. 1998. Int. Immunol. 10:1347. Turco MC, et al. 1988. J. Immunol. 141:2275. Geppert TD, et al. 1989. J. Immunol. 142:3763. Wooden SL, et al. 2005. J. Immunol. 175:1383. Nagano M, et al. 2007. Blood 110:151. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope) Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations: Fu J et al. 2019. Cell stem cell. 24(2):227-239 . PubMed Chen WT, et al. 2018. J Invest Dermatol. 138:1546. PubMed Khatri A, et al. 2023. JCI Insight. 8:. PubMed Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed Mirlashari MR, et al. 2021. Transfusion. 61:1222. PubMed Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed Sim MJW, et al. 2022. Elife. 11: . PubMed Moon JS, et al. 2023. Nat Commun. 14:319. PubMed Zhu Z, et al. 2022. Front Oncol. 12:814312. PubMed Gallen C, et al. 2022. Vaccines (Basel). 10:. PubMed Tsuchiya N, et al. 2018. Oncoimmunology. 7:e1377872. PubMed Abdul–Salam VB, et al. 2019. Circ Res. 124:52:00. PubMed Jimenez-Duran G, et al. 2022. Front Immunol. 13:918551. PubMed Chou JM, et al. 2022. Front Microbiol. 13:883597. PubMed Nguyen R, et al. 2021. Cancer Immunol Immunother. 70:721. PubMed Andersen R, et al. 2018. Cancer Immunol Res. 0.404166667. PubMed Laing B, et al. 2010. J Thorac Cardiovasc Surg. 139:1402. PubMed Hsiue EH, et al. 2021. Science. 371:. PubMed Rennier K, et al. 2020. Clin Cancer Res. 26:5019. PubMed Wroblewska A et al. 2018. Cell. 175(4):1141-1155 . PubMed Garrido C, et al. 2018. JCI Insight. 3:e120121. PubMed Willimsky G, et al. 2021. Elife. 10:. PubMed Takeuchi M, et al. 2010. J Mol Cell Biol. 0.179861111. PubMed Mirandola L, et al. 2017. Oncotarget. 8:74378. PubMed Sharma M, et al. 2020. Front Immunol. 11:1136. PubMed Moquin-Beaudry G, et al. 2022. Cell Rep Methods. 2:100153. PubMed Parker R, et al. 2020. bioRxiv. . PubMed A A, et al. 2016. Biotechnol Bioeng. 112: 2214-27. PubMed Fitzgerald W, et al. 2018. Am J Reprod Immunol. 80:e12860. PubMed Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed Gañán-Gómez I, et al. 2022. Nat Med. . PubMed Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed Yumoto K, et al. 2016. Sci Rep. 6:36520. PubMed Ruiz Cuevas MV, et al. 2021. Cell Reports. 34(10):108815. PubMed Higashi S, et al. 2022. J Cell Sci. 135:. PubMed Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed Liu Y, et al. 2017. Clin Cancer Res. 23(2):514-522. PubMed Blees A, et al. 2017. Nature.. 10.1038/nature24627. PubMed Han EX, et al. 2021. NPJ Regen Med. 6:40. PubMed Chen YL, et al. 2020. J Exp Med. 217:. PubMed Nöll A, et al. 2017. Proc Natl Acad Sci U S A. 114: E438 - E447. PubMed Makarkov AI, et al. 2019. NPJ Vaccines. 4:17. PubMed Mujib S, et al. 2017. JCI Insight. 2:e93687. PubMed Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed McLoughlin R, et al. 2008. J Immunol. 181:1323. PubMed Song S, et al. 2021. Front Immunol. 12:705140. PubMed Neuperger P, et al. 2021. Cancers (Basel). 14:. PubMed Pierini S, et al. 2020. JCI Insight. 5:00. PubMed Takahara M, et al. 2008. J Leukoc Biol. 83:742. PubMed Pettmann J, et al. 2021. eLife. 10:00. PubMed Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed Carlsten M, et al. 2019. Oncoimmunology. 8:e1534664. PubMed Jasmer B, et al. 2017. Oncotarget. 8:108643. PubMed Chen HC, et al. 2017. Immunol Cell Biol. 95:620. PubMed Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed Nosaka K, et al. 2021. Anticancer Res. 41:4741. PubMed
RRID: AB_314871 (BioLegend Cat. No. 311402)
Structure: Ig superfamily
Distribution: All nucleated cells
Function: Antigen presentation
Ligand/Receptor: CD3/TCR, CD8
Biology Area: Immunology, Innate Immunity
Molecular Family: MHC Antigens
Antigen References: 1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.
Gene ID: 3105
UniProt: View information about HLA-A on UniProt.org
Clone: W6/32
Regulatory Status: RUO
Other Names: Major Histocompatibility Class I, MHC class I
Isotype: Mouse IgG2a, κ